These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35006287)

  • 1. Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review.
    Srikantharajah D; Lloyd ME; Kiely PDW
    Rheumatol Int; 2022 Feb; 42(2):359-364. PubMed ID: 35006287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis - report of two cases and review of the literature.
    Chatterjee S; Prayson RA
    Semin Arthritis Rheum; 2020 Jun; 50(3):498-502. PubMed ID: 31806155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
    De Lorenzo R; Pinal-Fernandez I; Huang W; Albayda J; Tiniakou E; Johnson C; Milisenda JC; Casal-Dominguez M; Corse AM; Danoff SK; Christopher-Stine L; Paik JJ; Mammen AL
    Neurology; 2018 Jun; 90(23):e2068-e2076. PubMed ID: 29728522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
    Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A rare case of inclusion body myositis associated with anti-PM/Scl-75 antibodies].
    Yamamoto M; Tsuzaki K; Itani K; Tachibana N; Inoue M; Hamano T
    Rinsho Shinkeigaku; 2020 Apr; 60(4):264-267. PubMed ID: 32238743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
    Lazzaroni MG; Marasco E; Campochiaro C; DeVries-Bouwstra J; Gonzalez-Perez MI; Rojas-Serrano J; Hachulla E; Zanatta E; Barsotti S; Furini F; Triantafyllias K; Abignano G; Truchetet ME; De Luca G; De Langhe E; Hesselstrand R; Ingegnoli F; Bertoldo E; Smith V; Bellando-Randone S; Poormoghim H; Colombo E; Ceribelli A; Furloni A; Zingarelli S; Cavazzana I; Franceschini F; Del Galdo F; Denton CP; Cavagna L; Distler O; Allanore Y; Airò P;
    Rheumatology (Oxford); 2021 Nov; 60(11):5028-5041. PubMed ID: 33580257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report.
    Chinniah KJ; Mody GM
    Afr Health Sci; 2017 Jun; 17(2):593-596. PubMed ID: 29062359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
    Leclair V; Galindo-Feria AS; Dastmalchi M; Holmqvist M; Lundberg IE
    Rheumatology (Oxford); 2019 Jul; 58(7):1214-1220. PubMed ID: 30690633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis.
    Wielosz E; Dryglewska M; Majdan M
    Ann Agric Environ Med; 2021 Mar; 28(1):189-192. PubMed ID: 33775087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulins in systemic sclerosis management. A large multicenter experience.
    Tandaipan J; Guillén-Del-Castillo A; Simeón-Aznar CP; Carreira PE; De la Puente C; Narváez J; Lluch J; Rubio-Rivas M; Alegre-Sancho JJ; Bonilla G; Moriano C; Casafont-Sole I; García-Vicuña R; Ortiz-Santamaría V; Riera E; Atienza-Mateo B; Blanco R; Galisteo C; Gonzalez-Martin JJ; Pego-Reigosa JM; Pros A; Heredia S; Castellví I
    Autoimmun Rev; 2023 Nov; 22(11):103441. PubMed ID: 37708984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
    Oddis CV; Okano Y; Rudert WA; Trucco M; Duquesnoy RJ; Medsger TA
    Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?
    Janardana R; Nair AM; Surin AK; Prakash JAJ; Gowri M; Danda D
    Clin Rheumatol; 2019 Nov; 38(11):3179-3187. PubMed ID: 31309339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.
    Aguila LA; Lopes MR; Pretti FZ; Sampaio-Barros PD; Carlos de Souza FH; Borba EF; Shinjo SK
    Clin Rheumatol; 2014 Aug; 33(8):1093-8. PubMed ID: 24989017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PM-Scl antibody in patients with systemic sclerosis.
    Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy.
    Fanouriakis A; Lazarini A; Sofianos I; Papadopoulos C; Bagiazidou E; Balanika A; Elezoglou A
    Rheumatology (Oxford); 2021 Nov; 60(11):e378-e380. PubMed ID: 33956080
    [No Abstract]   [Full Text] [Related]  

  • 17. Overlap syndrome of progressive systemic sclerosis and polymyositis: report of 40 cases.
    Yuan X; Chen M
    Chin Med Sci J; 1991 Jun; 6(2):107-9. PubMed ID: 1804374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome.
    Coppo P; Clauvel JP; Bengoufa D; Oksenhendler E; Lacroix C; Lassoued K
    Rheumatology (Oxford); 2002 Sep; 41(9):1040-6. PubMed ID: 12209039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab.
    Mazeda C; Cunha R; Ferreira PG; Barcelos A; Aguiar R
    Rheumatol Int; 2022 Jul; 42(7):1265-1269. PubMed ID: 34086073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody.
    Marie I; Lahaxe L; Benveniste O; Delavigne K; Adoue D; Mouthon L; Hachulla E; Constans J; Tiev K; Diot E; Levesque H; Boyer O; Jouen F
    Br J Dermatol; 2010 Feb; 162(2):337-44. PubMed ID: 19845665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.